Presentation (CTI)

OBJECTIVES: Specialty drugs—high-cost therapies for complex conditions such as cancer, autoimmune disorders, and rare diseases requiring specialized handling or monitoring—represent <5% of prescriptions yet account for 54% of pharmaceutical spending (approximately $263 billion in 2024), up from 47% in 2019. This study examines FDA approvals of specialty drugs from 2000-2024 to estimate their share of total approvals and describe key characteristics such as orphan status, therapeutic area, and use of expedited review pathways.
METHODS: We identified novel drug and biologic approvals from the FDA’s New Molecular Entity database for 2000-2024, excluding withdrawn products. Because the FDA does not classify specialty drugs, we assigned designations using specialty lists from CVS Caremark, Express Scripts, and OptumRx; we considered a drug appearing on at least one list a specialty medication. We automatically classified cell and gene therapies as specialty due to their high prices and management requirements. For each specialty therapy, we categorized initial and follow-on indications by orphan status, cancer indication, and expedited review type. We assessed temporal trends using Poisson regression, adjusting for total annual approvals via a log offset.
RESULTS: Of 897 novel drugs approved between 2000 and 2024, 516 (57%) were specialty therapies, increasing by about 3% annually (β=0.0295, p<0.001). Including follow-on indications, 947 specialty drug-indication pairs were identified. Among these, 55% (525) had an orphan designation and 46% (435) treated cancer. The FDA granted expedited reviews to 251 pairs (27%) through one program, 239 (25%) through two, 122 (13%) through three, and 14 (1%) through four programs.
CONCLUSIONS: Specialty drug approvals continue to rise, reflecting scientific advances and policy incentives supporting development of high-cost, complex therapies. While these treatments can offer meaningful clinical benefits, their increasing prevalence and prices pose affordability challenges, underscoring the need for policies balancing innovation with equitable access.